Volume 153, Issue 3, Pages (June 2019)

Slides:

Advertisements

Similar presentations

GCIG trials for rare ovarian histologies Edward L. Trimble, MD, MPH National Cancer Institute, USA.

Advertisements

Identification of Novel Candidate Oncogenes and Tumor Suppressors in Malignant Pleural Mesothelioma Using Large-Scale Transcriptional Profiling Gavin J.

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Nicoletta Colombo, Martin Gore

Volume 144, Issue 1, Pages (January 2017)

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Treatment of stage I NSCLC in elderly patients: A population-based matched-pair comparison of stereotactic radiotherapy versus surgery David Palma, Otto.

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 16, Issue 8, Pages (August 2015)

Volume 148, Issue 1, Pages (January 2018)

Are patients willing to travel for better ovarian cancer care?

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

Volume 150, Issue 3, Pages (September 2018)

Volume 61, Issue 6, Pages (June 2012)

Volume 149, Issue 2, Pages (May 2018)

Volume 138, Issue 1, Pages (July 2015)

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

Volume 147, Issue 1, Pages 3-10 (October 2017)

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

A Comparison of Quality-of-Life Domains and Clinical Factors in Ovarian Cancer Patients: A Gynecologic Oncology Group Study Vivian E. von Gruenigen,

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 18, Issue 3, Pages (March 2017)

Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum E.E. Stevens, J.N. Bottsford-Miller,

Volume 145, Issue 2, Pages (May 2017)

Volume 387, Issue 10023, Pages (March 2016)

Volume 142, Issue 3, Pages (September 2016)

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Photodynamic Therapy for Early Stage Central Type of Lung Cancer

Volume 146, Issue 1, Pages (July 2017)

Volume 152, Issue 1, Pages (January 2019)

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

Volume 151, Issue 1, Pages (October 2018)

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 147, Issue 2, Pages (November 2017)

Volume 152, Issue 1, Pages (January 2019)

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Volume 143, Issue 2, Pages (November 2016)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

The origins of multidisciplinary cancer care

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer David R. Spigel,

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 1, Pages (October 2017)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases

Volume 152, Issue 1, Pages (January 2019)

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Volume 147, Issue 3, Pages (December 2017)

Volume 150, Issue 3, Pages (September 2018)

Volume 130, Issue 1, Pages (July 2013)

Full inguinofemoral lymphadenectomy after positive sentinel inguinofemoral lymph node is associated with greater overall survival in patients with stage.

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Volume 151, Issue 1, Pages (October 2018)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Volume 130, Issue 1, Pages (July 2013)

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Volume 147, Issue 3, Pages (December 2017)

A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

A Comparison of Quality-of-Life Domains and Clinical Factors in Ovarian Cancer Patients: A Gynecologic Oncology Group Study Vivian E. von Gruenigen,

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 153, Issue 3, Pages 541-548 (June 2019) An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor Martin Gore, Allan Hackshaw, William E. Brady, Richard T. Penson, Richard Zaino, W. Glenn McCluggage, Raji Ganesan, Nafisa Wilkinson, Timothy Perren, Ana Montes, Jeffrey Summers, Rosemary Lord, Graham Dark, Gordon Rustin, Melanie Mackean, Nicholas Reed, Sean Kehoe, Michael Frumovitz, Helen Christensen, Amanda Feeney, Jonathan Ledermann, David M. Gershenson Gynecologic Oncology Volume 153, Issue 3, Pages 541-548 (June 2019) DOI: 10.1016/j.ygyno.2019.03.256 Copyright © 2019 The Authors Terms and Conditions

Fig. 1 Overall survival according to the two main protocol-defined comparisons, ‘oxaliplatin + capecitabine versus no oxaliplatin + capecitabine’ and ‘bevacizumab versus no bevacizumab’, for all 50 patients (Panels A and B), and for patients with confirmed mEOC after central pathology review (Panels C and D). There was no evidence of an interaction between these two main experimental regimens (Panels A & B); interaction p = 0.37 for OS. Gynecologic Oncology 2019 153, 541-548DOI: (10.1016/j.ygyno.2019.03.256) Copyright © 2019 The Authors Terms and Conditions